# Ionis Posts $243 Million in Q3 Revenue and $0.66 Per-Share Loss

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52882
Published: 2026-11-10T07:18:32.000Z
Updated: 2026-11-10T07:18:32.000Z
Section: Business

> The reporting period ended Sept. 30, 2026.

Ionis Pharmaceuticals recorded $243 million in revenue and a net loss per share of $0.66 under generally accepted accounting principles (GAAP) for Q3 2026, which ended Sept. 30.

GAAP refers to the accounting rules used to prepare financial statements.